LAUDER

Lauder family pledges $200M to its Alzheimer's research work

The FDA has approved two drugs that target the buildup of amyloid, though the 2021 approval of Biogen's Aduhelm garnered controversy after the agency overruled its own independent scientific advisers. Legembi, a second drug, approved in January, is the first that's been convincingly shown to slow the decline in memory and thinking that defines Alzheimer's by targeting the disease's underlying biology.